Published in Nature on August 02, 2012
Down Syndrome Biomarker Initiative (DSBI) (DSBI) | NCT02141971
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell (2013) 4.45
Rare-variant association analysis: study designs and statistical tests. Am J Hum Genet (2014) 3.42
Validating therapeutic targets through human genetics. Nat Rev Drug Discov (2013) 2.94
Microglia: scapegoat, saboteur, or something else? Science (2013) 2.94
Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet (2014) 2.89
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature (2013) 2.79
Therapeutic genome editing: prospects and challenges. Nat Med (2015) 2.42
The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med (2016) 2.31
Improving the accuracy and efficiency of identity-by-descent detection in population data. Genetics (2013) 2.26
iPS cells: a game changer for future medicine. EMBO J (2014) 2.15
An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med (2014) 1.99
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Resting state functional connectivity in preclinical Alzheimer's disease. Biol Psychiatry (2013) 1.86
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature (2016) 1.80
Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY) (2014) 1.77
Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci (2013) 1.77
Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol (2014) 1.76
Alzheimer's disease genetics: from the bench to the clinic. Neuron (2014) 1.65
Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab (2012) 1.64
Biology and genetics of prions causing neurodegeneration. Annu Rev Genet (2013) 1.63
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol (2014) 1.52
Exome sequencing and complex disease: practical aspects of rare variant association studies. Hum Mol Genet (2012) 1.52
A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med (2014) 1.51
Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc Natl Acad Sci U S A (2014) 1.49
Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci (2014) 1.47
Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of APP processing. PLoS One (2015) 1.47
Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry (2014) 1.42
Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease. PLoS Genet (2016) 1.39
Perinatal Choline Supplementation Reduces Amyloidosis and Increases Choline Acetyltransferase Expression in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice. PLoS One (2017) 1.39
Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med (2013) 1.38
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem (2014) 1.37
An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int J Mol Sci (2012) 1.37
Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet (2014) 1.36
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med (2013) 1.36
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 1.30
Alzheimer's disease: analyzing the missing heritability. PLoS One (2013) 1.28
Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol (2013) 1.25
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol (2014) 1.21
Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways. Curr Genet Med Rep (2014) 1.18
Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov (2012) 1.18
Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry (2013) 1.18
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
In search of low-frequency and rare variants affecting complex traits. Hum Mol Genet (2013) 1.14
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement (2014) 1.12
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov (2013) 1.12
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta (2012) 1.11
BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Mol Neurodegener (2012) 1.11
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol (2015) 1.11
Suspected non-Alzheimer disease pathophysiology - concept and controversy. Nat Rev Neurol (2016) 1.10
The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med (2015) 1.09
Pharmacogenomics in clinical practice and drug development. Nat Biotechnol (2012) 1.08
Glutathione and mitochondria. Front Pharmacol (2014) 1.08
The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J Biol Chem (2014) 1.07
Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. Nat Genet (2017) 1.07
Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem (2014) 1.06
Revitalizing psychiatric therapeutics. Neuropsychopharmacology (2014) 1.05
Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis (2013) 1.05
β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem (2012) 1.05
Amgen punts on deCODE's genetics know-how. Nat Biotechnol (2013) 1.05
Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics (2013) 1.05
Rare variant association studies: considerations, challenges and opportunities. Genome Med (2015) 1.05
Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets. PLoS Genet (2013) 1.04
Amyloid-ß-directed immunotherapy for Alzheimer's disease. J Intern Med (2014) 1.04
A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nat Med (2014) 1.02
Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain (2015) 1.01
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther (2014) 1.00
Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res (2015) 0.98
Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener (2012) 0.98
Reducing pervasive false-positive identical-by-descent segments detected by large-scale pedigree analysis. Mol Biol Evol (2014) 0.98
On the lag phase in amyloid fibril formation. Phys Chem Chem Phys (2015) 0.98
From genetic discovery to future personalized health research. N Biotechnol (2012) 0.98
β-Amyloid oligomers in aging and Alzheimer's disease. Front Aging Neurosci (2013) 0.98
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell (2015) 0.96
Pharmacologic inhibition of ROCK2 suppresses amyloid-β production in an Alzheimer's disease mouse model. J Neurosci (2013) 0.96
Genome-scale neurogenetics: methodology and meaning. Nat Neurosci (2014) 0.96
Disease variants in genomes of 44 centenarians. Mol Genet Genomic Med (2014) 0.96
A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease Aβ production. Cell Rep (2013) 0.96
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem (2012) 0.96
Galactic cosmic radiation leads to cognitive impairment and increased aβ plaque accumulation in a mouse model of Alzheimer's disease. PLoS One (2012) 0.96
Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc Natl Acad Sci U S A (2015) 0.96
Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease. Neurobiol Aging (2014) 0.95
Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer's disease. Front Mol Neurosci (2015) 0.94
Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains. Elife (2015) 0.93
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci (2012) 0.93
ABCC5, a gene that influences the anterior chamber depth, is associated with primary angle closure glaucoma. PLoS Genet (2014) 0.92
Genomic view of bipolar disorder revealed by whole genome sequencing in a genetic isolate. PLoS Genet (2014) 0.92
The central molecular clock is robust in the face of behavioural arrhythmia in a Drosophila model of Alzheimer's disease. Dis Model Mech (2014) 0.92
Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry (2015) 0.92
Polygenic Analysis of Late-Onset Alzheimer's Disease from Mainland China. PLoS One (2015) 0.92
Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci (2012) 0.92
A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet (2007) 52.68
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology (2007) 12.42
Detection of sharing by descent, long-range phasing and haplotype imputation. Nat Genet (2008) 9.69
MDS Cognitive Performance Scale. J Gerontol (1994) 9.61
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature (1999) 5.48
Fine-scale recombination rate differences between sexes, populations and individuals. Nature (2010) 4.74
Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77
Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One (2012) 3.11
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci (2009) 2.86
Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet (2011) 2.48
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (2009) 2.30
APP processing in Alzheimer's disease. Mol Brain (2011) 2.02
Molecular genetics of Alzheimer's disease. Biol Psychiatry (2000) 1.99
Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer's disease. Neurology (1993) 1.64
Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem (2001) 1.52
Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J Neurochem (2003) 1.35
Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol (2010) 1.16
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
A high-resolution recombination map of the human genome. Nat Genet (2002) 28.66
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Genetics of gene expression and its effect on disease. Nature (2008) 21.35
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet (2010) 14.81
A common inversion under selection in Europeans. Nat Genet (2005) 13.66
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 12.51
Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet (2008) 12.43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Rate of de novo mutations and the importance of father's age to disease risk. Nature (2012) 11.92
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81
Common variants conferring risk of schizophrenia. Nature (2009) 10.37